公开(公告)号：US10899752B2

公开(公告)日：2021-01-26

申请号：US16394762

申请日：2019-04-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Shinkichi Suzuki ,  Hiroki Sakamoto ,  Masami Yamada ,  Minoru Nakamura ,  Makoto Kamata ,  Kenichiro Shimokawa ,  Masataka Murakami ,  Jinichi Yonemori ,  Takuto Kojima

IPC: C07D413/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D471/04 ,  C07D491/107 ,  C07D265/22 ,  C07F7/02 ,  A61P25/28 ,  C07D417/10 ,  C07F7/08

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

公开(公告)号：US10323027B2

公开(公告)日：2019-06-18

申请号：US15735418

申请日：2016-06-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Shinkichi Suzuki ,  Hiroki Sakamoto ,  Masami Yamada ,  Minoru Nakamura ,  Makoto Kamata ,  Kenichiro Shimokawa ,  Masataka Murakami ,  Jinichi Yonemori ,  Takuto Kojima

IPC: C07D413/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D471/04 ,  C07D265/22 ,  C07D491/107 ,  C07F7/02 ,  A61P25/28 ,  C07D417/10 ,  C07F7/08

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

公开(公告)号：US20220017530A1

公开(公告)日：2022-01-20

申请号：US17475733

申请日：2021-09-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Kazuaki Takami ,  Masaki Seto ,  Shinobu Sasaki ,  Haruhi Ando ,  Masaki Ogino ,  Tomoko Ohashi ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Yasuhiro Tsukimi ,  Masami Yamada ,  Kenichiro Shimokawa ,  Takeshi Wakabayashi ,  Masataka Murakami ,  Makoto Fushimi ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Tomohiro Ohashi ,  Hideo Suzuki ,  Hironobu Maezaki ,  Ayumu Sato ,  Yasutomi Asano ,  Steve Swann

IPC: C07D491/048 ,  A61P1/10 ,  A61K31/4355

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US10428056B2

公开(公告)日：2019-10-01

申请号：US16113635

申请日：2018-08-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Shinkichi Suzuki ,  Hiroki Sakamoto ,  Masami Yamada ,  Minoru Nakamura ,  Makoto Kamata ,  Kenichiro Shimokawa ,  Masataka Murakami ,  Jinichi Yonemori ,  Takuto Kojima

IPC: C07D471/04 ,  C07D413/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D265/22 ,  C07D491/107 ,  C07F7/02 ,  A61P25/28 ,  C07D417/10 ,  C07F7/08

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

公开(公告)号：US11236099B2

公开(公告)日：2022-02-01

申请号：US16622632

申请日：2018-06-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kazuaki Takami ,  Masaki Seto ,  Shinobu Sasaki ,  Haruhi Ando ,  Masaki Ogino ,  Tomoko Ohashi ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Yasuhiro Tsukimi ,  Masami Yamada ,  Kenichiro Shimokawa ,  Takeshi Wakabayashi ,  Masataka Murakami ,  Makoto Fushimi ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Tomohiro Ohashi ,  Hideo Suzuki ,  Hironobu Maezaki ,  Ayumu Sato ,  Yasutomi Asano ,  Steve Swann

IPC: C07D491/048 ,  A61K31/4355 ,  A61P1/10

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US10548899B2

公开(公告)日：2020-02-04

申请号：US15769295

申请日：2016-10-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takahiro Sugimoto ,  Shinkichi Suzuki ,  Hiroki Sakamoto ,  Masami Yamada ,  Minoru Nakamura ,  Makoto Kamata ,  Kenichiro Shimokawa ,  Masaki Ogino ,  Eiji Kimura ,  Masataka Murakami ,  Takuto Kojima ,  Jinichi Yonemori

IPC: A61K31/53 ,  A61K31/517 ,  C07D403/06 ,  C07D403/10 ,  C07D405/14 ,  C07D401/14 ,  C07D239/88 ,  C07D401/06 ,  A61P25/28 ,  A61P25/04 ,  A61P25/18 ,  A61P25/16

Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.

公开(公告)号：US09732086B2

公开(公告)日：2017-08-15

申请号：US14443598

申请日：2013-11-18

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Shinkichi Suzuki ,  Masami Yamada ,  Makoto Kamata ,  Takuto Kojima ,  Ikuo Fujimori ,  Kenichiro Shimokawa

IPC: C07D221/02 ,  A61K31/44 ,  C07D487/04 ,  C07D401/14 ,  C07D405/14 ,  C07D401/06 ,  C07D403/10 ,  C07D403/14 ,  C07D405/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D453/02 ,  C07D471/04 ,  C07D471/14 ,  C07D209/46 ,  C07D519/00

Abstract: Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO2—; R1 is a C1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R1 is not a C1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X1 is —CRa═ or —N═; X2 is —CRb═ or —N═; X3 is —CRc= or —N═; Ra, Rb and Rc are each a C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, C3-6 cycloalkyl group, C3-6 cycloalkoxy group or C6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.

公开(公告)号：US11034700B2

公开(公告)日：2021-06-15

申请号：US16491794

申请日：2018-03-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi Mikami ,  Masaki Daini ,  Yuhei Miyanohana ,  Hideo Suzuki ,  Kenichiro Shimokawa ,  Yuichi Kajita ,  Masaki Ogino ,  Tatsuki Koike ,  Kohei Takeuchi

IPC: A61K31/40 ,  C07D491/107 ,  C07D207/12 ,  C07D207/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D405/10 ,  C07D409/06 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12

Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10208046B2

公开(公告)日：2019-02-19

申请号：US15311025

申请日：2015-05-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Kenichiro Shimokawa ,  Takuto Kojima ,  Hiroki Sakamoto ,  Ikuo Fujimori ,  Minoru Nakamura ,  Masami Yamada ,  Masataka Murakami ,  Makoto Kamata ,  Shinkichi Suzuki

IPC: A61K31/437 ,  C07D487/04 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/501 ,  A61K31/519 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH═ or —N═, or a salt thereof.

公开(公告)号：US10087150B2

公开(公告)日：2018-10-02

申请号：US15799379

申请日：2017-10-31

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Shinkichi Suzuki ,  Hiroki Sakamoto ,  Masami Yamada ,  Minoru Nakamura ,  Makoto Kamata ,  Kenichiro Shimokawa ,  Takuto Kojima

IPC: C07D265/22 ,  C07D413/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D471/04 ,  C07D491/107 ,  C07F7/02

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.